share_log

BRIEF-Blueprint Medicines Announces EMA Validation Of Type Ii Variation Marketing Authorization Application For Ayvakyt® (Avapr

BRIEF-Blueprint Medicines Announces EMA Validation Of Type Ii Variation Marketing Authorization Application For Ayvakyt® (Avapr

Brief-Blueprint Medicines宣布EMA验证Ayvakyt®(AVAPR)的II型变异营销授权申请
路透社 ·  2021/03/03 21:15

March 3 (Reuters) - Blueprint Medicines Corp :
   * BLUEPRINT MEDICINES ANNOUNCES EMA VALIDATION OF TYPE II VARIATION MARKETING AUTHORIZATION APPLICATION FOR AYVAKYT® (AVAPRITINIB) FOR THE TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS
   * BLUEPRINT MEDICINES CORP - EUROPEAN COMMISSION HAS GRANTED ORPHAN MEDICINAL PRODUCT DESIGNATION TO AYVAKYT FOR TREATMENT OF MASTOCYTOSIS

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)

路透3月3日电-Blueprint Medicines Corp：*Blueprint Medicine宣布EMA验证AYVAKYT®(AVAPRITINIB)用于治疗晚期系统性肥大细胞增多症的II型变异营销授权申请*Blueprint Medicine Corp-欧盟委员会已授予AYVAKYT治疗肥大细胞增多症的孤儿药品称号Eikon的源文本：进一步的公司报道：(Reurs.Briefs@thomsonreurs.com；)

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发